SIMON WATTS (National—North Shore): Thank you very much, Madam Chair, and thank you to the Minister for those contributions. I want to dig a little bit deeper into Part 3, clause 62(1)(c) in regards to operational budget, and I guess the broader theme here is in regards to—I think we'd all acknowledge one of the challenges with Pharmac and the way in which it operates. What I'm wanting in my question for the Minister is why haven't we gone further in regards to this aspect. Is it that when benefits are calculated in regards to the benefit payback from the introduction of a pharmaceutical drug, the benefits generally are only those related to the health sphere related to that drug but do not go broader to other benefits? What I mean by that is the provision of pharmaceutical medication may, in effect, allow someone to go back into the workforce, and so the benefits in terms of the economic benefit of someone working or not is not necessarily going to be felt within the healthcare system, but it may be felt within, potentially, the welfare system, because that person would transition from welfare into a paid job. 